RecruitingNot Applicable

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

France637 participantsStarted 2024-07-01

Plain-language summary

Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography

Who can participate

Age range

80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged ≥ 80 years * Hospitalised for decompensation of heart failure in the last 12 months * Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm) * Subjects able to undergo a bone scintigraphy scan * Subjects willing to participate Exclusion Criteria: * Subjects refusing to participate * Subjects admitted to palliative care unit. * Subjects under guardianship * Subjects with a definite diagnosis of cardiac amyloidosis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Assessment of the number of patients with cardiac amyloidosis according bon scintigraphy

Timeframe: At inclusion

Trial details

NCT IDNCT06427304

SponsorGérond'if

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07-02

Contact for this trial

Isabelle Dufour

+33 (0) 185781011 isabelle.dufour@gerondif.org

View on ClinicalTrials.gov More Cardiac Amyloidosis trials